Tests radioactive iodine I-131 MIBG in hard-to-treat neuroblastoma and related tumors
Tests radioactive iodine I-131 MIBG in children and adults with resistant neuroblastoma or pheochromocytoma.
Key facts
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Where
- New York, United StatesSee the site
- Trial code
- Registry title
- Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 200 people, planned
- Started
- May 2006
- Expected to end
- May 2027
- Type of study
- Interventional
- Treatments tested
- iobenguane I 131
- Record updated
- 29 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with neuroblastoma, or with malignant pheochromocytoma or paraganglioma, that came back, got worse or did not respond to standard treatment, and that shows up on an MIBG scan.
- Age
- Older than 1 year for neuroblastoma. Between 1 and 21 years for malignant pheochromocytoma or paraganglioma.
- Sex
- All sexes can join.
- Disease stage
- Neuroblastoma that progressed, came back or did not fully respond to standard therapy, or malignant pheochromocytoma or paraganglioma. The disease must take up MIBG and be measurable on an MIBG scan.
- Earlier treatment
- At least 2 weeks since any biologic therapy and 3 weeks since the last chemotherapy. Patients on the high-dose arm, and those with pheochromocytoma or paraganglioma, need frozen stem cells of their own ready for re-infusion.
- Biomarker or test result
- The tumor must take up MIBG on an MIBG scan. For neuroblastoma, the diagnosis is confirmed by tissue examination, or by bone marrow involvement plus high urinary catecholamines.
Main reasons for not taking part
- Severe organ problems (kidney, heart, liver, lung, gut or nerves) worse than grade 2
- Serious active infection not controlled by antibiotics
- Pregnancy
- Cannot or will not follow the radiation safety rules
- Life expectancy shorter than 8 weeks
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Patients must have the diagnosis of NB in accordance with the International Criteria, i.e., either histopathology (confirmed by the MSKCC Department of Pathology) or BM involvement plus elevated urinary catecholamines
- Must have a history of tumor progression or recurrence or failure to achieve complete response with standard therapy
- Patients must have MIBG-avid NB and evaluable disease on MIBG scan at time of enrollment on protocol
- Prior Therapy: At least 2 weeks should have elapsed since any biologic therapy. Three weeks should have elapsed since last dose of chemotherapy
- Age >1 year
- Determination that radiation safety restrictions during therapy period can be implemented
- Stem cells: Patients for high does must have an autologous hematopoietic stem cell product cryopreserved and available for re-infusion after MIBG treatment. Patients for low dose do not require cryopreserved autologous hematopoietic stem cell product available. The minimum dose for peripheral blood stem cells is 2 X106 CD34+ cells/kg
- Minimum life expectancy of eight weeks
- Signed informed consent indicating awareness of the investigational nature of this program
- Patients must have the diagnosis of malignant CCT i.e. malignant pheochromocytoma or malignant paraganglioma
- Patients must have MIBG-avid malignant CCT and evaluable disease on MIBG scan at time of enrollment on protocol
- Prior Therapy: At least 2 weeks should have elapsed since any biologic therapy. Three weeks should have elapsed since last dose of chemotherapy
- Age between 1 and 21 years and able to cooperate with radiation safety restrictions during therapy period
- Stem cells: Patients must have an autologous hematopoietic stem cell product cryopreserved and available for re-infusion after MIBG treatment. The minimum dose for peripheral blood stem cells is 2 X106 CD34+ cells/kg
- Minimum life expectancy of eight weeks
- Signed informed consent indicating awareness of the investigational nature of this program
Who cannot take part
- Inability or unwillingness to comply with radiation safety procedures or protocol requirements
- Severe major organ toxicity. Specifically, renal, cardiac, hepatic, pulmonary, gastrointestinal and neurologic toxicity should all be grade 2 or less. A grade 3 hearing deficit is acceptable
- Active serious infections not controlled by antibiotics
- Pregnant women are excluded for fear of danger to the fetus. Therefore negative pregnancy test is required for all women of child-bearing age, and appropriate contraception is used during the study period
Where in United States
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Ellen Basu, MD, PhDTaking people
About the trial
What the trial wants to find out
The purpose of this research study is to find how active and safe 131 I-MIBG is in patients with resistant neuroblastoma, malignant pheochromocytoma and malignant paraganglioma.
The group in the trial
- RadiationTreatment being tested
Patients will be treated with IV 131I-MIBG using 1-2 high dose(s) or up to 16 low doses. Thyroid protection is commenced seven days (+/-2 days) prior to administration of 131I-MIBG and continued for up to 42 days after each 131I-MIBG treatment. Given that this is an open access protocol, re-enrollment is allowed per PI discretion. Patients who received this treatment previously are allowed to be re-enrolled if they meet the eligibility criteria. Re-enrollment can be to the same arm previously treated on (high dose versus low dose) or to the other arm. Patients will not be eligible for re-enrollment if they have already received 16 low doses or 4 high doses of 131I-MIBG.
Treatment: iobenguane I 131
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Open Access Protocol of Targeted Radiotherapy With I-metaiodobenzylguanidine (I-MIBG) in Patients With Resistant Neuroblastoma or Malignant Chromaffin Cell Tumors
- Plain-language title
- Tests radioactive iodine I-131 MIBG in hard-to-treat neuroblastoma and related tumorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Feasibility of Administering High-Dose (131) I-MIBG Therapy to Children with High-Risk Neuroblastoma Without Lead-Lined Rooms.Pediatric blood & cancer, 2016
- Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016
- Record updated
- 29 May 2026